Cerevel Therapeutics Holdings CERE

$ 44.96 0.0%

Quarterly report 2024-Q1
added 05-08-2024

Cerevel Therapeutics Holdings Financial Statements 2011-2024 | CERE

Annual Financial Statements Cerevel Therapeutics Holdings

	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
Market Cap	6.68 B	4 B	4.43 B	1.22 B	-	-	-	-	-	-	-	-	-
Shares	162 M	151 M	137 M	73.6 M	-	-	-	-	-	-	-	-	-
Historical Prices	41.2	26.4	32.4	16.6	-	-	-	-	-	-	-	-	-
Net Income	-433 M	-352 M	-225 M	-152 M	-	-	-	-	-28.2 M	-29.3 M	-32.5 M	-29.4 M	-
Revenue	-	-	-	-	-	-	-	-	2.72 M	2.4 M	5.24 M	5.37 M	-
Cost of Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-
Gross Profit	-	-	-	-	-	-	-	-	-2.55 M	-617 K	-1 M	2.99 M	-
Operating Income	-447 M	-368 M	-220 M	-149 M	-83.5 M	-	-	-	-	-	-	-	-
Interest Expense	10.6 M	3.92 M	-5.39 M	-3.27 M	-46.4 M	-	-	-	-	-	-	-	-
EBITDA	-442 M	-363 M	-217 M	-149 M	-	-	-	-	-27.5 M	-27.7 M	-30.7 M	-26.7 M	-
Operating Expenses	447 M	368 M	220 M	149 M	-	-	-	-	30.9 M	31.7 M	37.8 M	31.8 M	-
General and Administrative Expenses	113 M	87.6 M	58.2 M	45.8 M	-	-	-	-	15.9 M	14.5 M	15.2 M	12.6 M	-

All numbers in USD currency

Quarterly Income Statement Cerevel Therapeutics Holdings

	2024-Q1	2023-Q4	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
Shares	182 M	181 M	157 M	157 M	157 M	157 M	152 M	148 M	148 M	148 M	144 M	127 M	127 M	127 M	63.3 M	60.9 M	60.9 M	60.9 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net Income	-132 M	-	-96.4 M	-99.5 M	-104 M	-	-99.9 M	-90.5 M	-68.3 M	-	-62.1 M	-53.2 M	-51 M	-	-39 M	-26.7 M	-53.2 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Cost of Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Gross Profit	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Operating Income	-143 M	-	-111 M	-96.8 M	-99.6 M	-	-95.1 M	-93 M	-72.5 M	-	-54.5 M	-50.5 M	-50.6 M	-	-34.4 M	-35.2 M	-37.7 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Interest Expense	2.65 M	-	2.64 M	2.64 M	2.64 M	-	1.29 M	1.87 M	3.94 M	-	-7.54 M	-2.74 M	-425 K	-	-4.68 M	8.42 M	-15.7 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
EBITDA	-141 M	-	-	-	-98.2 M	-	-91.5 M	-93 M	-71.4 M	-	-52.9 M	-50.5 M	-50.5 M	-	-34 M	-34.9 M	-37.6 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Operating Expenses	143 M	-	111 M	96.8 M	99.6 M	-	95.1 M	93 M	72.5 M	-	54.5 M	50.5 M	50.6 M	-	34.4 M	35.2 M	37.7 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
General and Administrative Expenses	36.2 M	-	26.1 M	22.8 M	21.4 M	-	23.7 M	20.5 M	17.5 M	-	14.4 M	13.2 M	14 M	-	10.3 M	13 M	10.7 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

All numbers in USD currency